Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease

Pediatric patients with heart disease are often treated with high doses of diuretics, which can lead to hypochloremic metabolic alkalosis. There are no data in children regarding the efficacy and safety of acetazolamide to treat hypochloremic metabolic alkalosis. Patients from January 2004 to June 2...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of therapeutics Vol. 14; no. 4; p. 331
Main Authors Moffett, Brady S, Moffett, Tiffany I, Dickerson, Heather A
Format Journal Article
LanguageEnglish
Published United States 01.07.2007
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Pediatric patients with heart disease are often treated with high doses of diuretics, which can lead to hypochloremic metabolic alkalosis. There are no data in children regarding the efficacy and safety of acetazolamide to treat hypochloremic metabolic alkalosis. Patients from January 2004 to June 2005 who received acetazolamide were identified. Inclusion criteria were: age less than 18 years, being a cardiology patient, diuretics use, and had received a 3-day course of acetazolamide. Demographic information was collected along with serum electrolytes, serum creatinine/blood urea nitrogen, urine output, pH, acid-base excess, concurrent medications, cardiac lesion/surgery, and incidence of adverse effects. Efficacy of acetazolamide was determined by comparing variables before and after the 3-day course. Statistical comparisons were made using Student's t-test. A total of 28 patients were identified, 7 of whom received oral acetazolamide, 21 intravenous acetazolamide. Patients were a median of 2.5 (range, 0.3-20) months of age, and 57% (17/28) were female. Seventy-one percent of the cohort received acetazolamide after cardiac surgery. There was no significant difference in any electrolyte, blood urea nitrogen, or serum creatinine from baseline, except for serum bicarbonate, which decreased (36.2 +/- 4.6 vs. 30.9 +/- 4.5 mmol/L, P < 0.001), and chloride, which increased (91.1 +/- 6.8 vs. 95.4 +/- 6.2, P < 0.03). Acid-base excess values and pH decreased during therapy in patients who had the laboratory values drawn (n = 22). No change in urine output at 8 hours (5.2 +/- 2.3 vs. 4.9 +/- 2.3 mL/kg/hr, P = 0.6) or 24 hours (4.7 +/- 1.5 vs. 4.3 +/- 1.4 mL/kg/hr, P = 0.18) occurred after administration of acetazolamide. Acetazolamide was safely used in pediatric patients with heart disease to lower serum bicarbonate and acid-base excess values and raise chloride values in hypochloremic metabolic alkalosis.
AbstractList Pediatric patients with heart disease are often treated with high doses of diuretics, which can lead to hypochloremic metabolic alkalosis. There are no data in children regarding the efficacy and safety of acetazolamide to treat hypochloremic metabolic alkalosis. Patients from January 2004 to June 2005 who received acetazolamide were identified. Inclusion criteria were: age less than 18 years, being a cardiology patient, diuretics use, and had received a 3-day course of acetazolamide. Demographic information was collected along with serum electrolytes, serum creatinine/blood urea nitrogen, urine output, pH, acid-base excess, concurrent medications, cardiac lesion/surgery, and incidence of adverse effects. Efficacy of acetazolamide was determined by comparing variables before and after the 3-day course. Statistical comparisons were made using Student's t-test. A total of 28 patients were identified, 7 of whom received oral acetazolamide, 21 intravenous acetazolamide. Patients were a median of 2.5 (range, 0.3-20) months of age, and 57% (17/28) were female. Seventy-one percent of the cohort received acetazolamide after cardiac surgery. There was no significant difference in any electrolyte, blood urea nitrogen, or serum creatinine from baseline, except for serum bicarbonate, which decreased (36.2 +/- 4.6 vs. 30.9 +/- 4.5 mmol/L, P < 0.001), and chloride, which increased (91.1 +/- 6.8 vs. 95.4 +/- 6.2, P < 0.03). Acid-base excess values and pH decreased during therapy in patients who had the laboratory values drawn (n = 22). No change in urine output at 8 hours (5.2 +/- 2.3 vs. 4.9 +/- 2.3 mL/kg/hr, P = 0.6) or 24 hours (4.7 +/- 1.5 vs. 4.3 +/- 1.4 mL/kg/hr, P = 0.18) occurred after administration of acetazolamide. Acetazolamide was safely used in pediatric patients with heart disease to lower serum bicarbonate and acid-base excess values and raise chloride values in hypochloremic metabolic alkalosis.
Author Moffett, Brady S
Dickerson, Heather A
Moffett, Tiffany I
Author_xml – sequence: 1
  givenname: Brady S
  surname: Moffett
  fullname: Moffett, Brady S
  email: bsmoffet@texaschildrenshospital.org
  organization: Department of Pharmacy, Texas Children's Hospital, Houston, TX 77030, USA. bsmoffet@texaschildrenshospital.org
– sequence: 2
  givenname: Tiffany I
  surname: Moffett
  fullname: Moffett, Tiffany I
– sequence: 3
  givenname: Heather A
  surname: Dickerson
  fullname: Dickerson, Heather A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17667206$$D View this record in MEDLINE/PubMed
BookMark eNo1j81KAzEUhbOo2B99A5G8wNTkZiaZWZaiVqm4qetyJ7nDROePJCL16S2oq3P4OHxwlmw2jAMxdiPFWorK3L08H9aiFlKRkqVAA7LIZ2whhSkyMLqYs2WM70JIKGV-yebSaG1A6AVzG0sJv8cOe--Ip5YCTifejIG3p2m0bTcG6r3l_XlWj925YfeB3Rh95H7gEzmPKZzxhMnTkCL_8qnlLWFI3PlIGOmKXTTYRbr-yxV7e7g_bHfZ_vXxabvZZxZApMzUthGmsqRs1djGNLYSANIVqBVaA9rWBYIDZykvq6oQRhlVCq2Vy40tAVbs9tc7fdY9ueMUfI_hdPy_Cz9KbVrn
CitedBy_id crossref_primary_10_1186_1471_2261_13_2
crossref_primary_10_5863_1551_6776_26_5_467
crossref_primary_10_7717_peerj_17316
crossref_primary_10_1097_MJT_0b013e31825e792c
crossref_primary_10_1017_S1047951121001451
crossref_primary_10_1016_j_transci_2014_03_002
crossref_primary_10_3928_01913913_20090101_05
crossref_primary_10_1111_jvim_16590
crossref_primary_10_1097_PCC_0000000000000633
crossref_primary_10_1097_PCC_0000000000000313
crossref_primary_10_5863_1551_6776_23_2_111
crossref_primary_10_1097_PCC_0000000000000994
crossref_primary_10_1097_PCC_0000000000000971
crossref_primary_10_1097_MJT_0000000000000147
crossref_primary_10_1177_2333794X21991014
crossref_primary_10_1177_2150135120942488
crossref_primary_10_1177_1060028013500468
crossref_primary_10_1161_JAHA_113_000434
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/MJT.0b013e3180a72154
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 17667206
Genre Journal Article
GroupedDBID ---
.Z2
0R~
23M
354
4Q1
4Q2
4Q3
53G
5GY
5VS
6J9
71W
8L-
AAAAV
AAHPQ
AAIQE
AARTV
AASCR
AAWTL
AAYOK
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACILI
ACNWC
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AEETU
AENEX
AFDTB
AHQNM
AHVBC
AINUH
AJIOK
AJNWD
AJNYG
AJZMW
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BQLVK
BS7
C45
CAG
CGR
COF
CS3
CUY
CVF
DIWNM
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F5P
FCALG
FL-
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
L-C
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
OHH
OJAPA
OLG
OLW
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
ZFV
ZZMQN
ID FETCH-LOGICAL-c220t-7bcf079ce3c9fcf7fc90221d5a63ac726cb5a2d2dce489950737380663d47c822
ISSN 1075-2765
IngestDate Sat Sep 28 07:43:57 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c220t-7bcf079ce3c9fcf7fc90221d5a63ac726cb5a2d2dce489950737380663d47c822
PMID 17667206
ParticipantIDs pubmed_primary_17667206
PublicationCentury 2000
PublicationDate 2007 Jul-Aug
PublicationDateYYYYMMDD 2007-07-01
PublicationDate_xml – month: 07
  year: 2007
  text: 2007 Jul-Aug
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of therapeutics
PublicationTitleAlternate Am J Ther
PublicationYear 2007
SSID ssj0012814
Score 1.8884944
Snippet Pediatric patients with heart disease are often treated with high doses of diuretics, which can lead to hypochloremic metabolic alkalosis. There are no data in...
SourceID pubmed
SourceType Index Database
StartPage 331
SubjectTerms Acetazolamide - therapeutic use
Alkalosis - chemically induced
Alkalosis - drug therapy
Blood Chemical Analysis
Carbonic Anhydrase Inhibitors - therapeutic use
Child, Preschool
Chlorides - blood
Diuretics - adverse effects
Diuretics - therapeutic use
Female
Heart Diseases - drug therapy
Humans
Infant
Infant, Newborn
Male
Sodium Bicarbonate - blood
Title Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease
URI https://www.ncbi.nlm.nih.gov/pubmed/17667206
Volume 14
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELaWIlW9VIU-oC2VD4gLhAbHieMjglYrpEUcgsQNORNbrMo-DuGw_IL-7I7jx2aBipZLFMVRlPj7Ys2MZ74hZNcwsJIsZcIVyITnWiUKGE9qpVSujTzS3BY4j86L4SU_u8qvBoPfvaylu7Y-hPsn60pegipeQ1xtlex_IBsfihfwHPHFIyKMx3_C-Bh0q-7ROZ2MG73vSqlcAubNYj6DG_TFu9z3Cd5WWwHgfXX7S93OrAhJlz3u23QEdVVf6mabXLcrWzdBpjZs7_T0JnoFXNE8H82M8fm_dq9-sYyv9kaqsTE22SCGbU_HNsXDV4ANnWnqQ60hLCFiCmtYSdEWSZhwjSDiUst7lOK9ddOXbT1az51O8OisWgZsU4VOqxOe7kE8n3QYW7lLwToNg2dGH6hsh6E1siZK2wLk3EZ9_G4UKzuN-PhJoQRTiu9PvZoVovWPe-CsdEZL9Y689d4GPXbU2SADPd0kr0c-n2KT7F045fLFAa16OB7QPXqx1DRfvCfNCtWopxpFqtEVqtFINRqpRsdTGqlGA9WopRrtqEY91T6Qy58_qpNh4ht0JMBY2iaiBpMKCToDacAIAxJNwqMmV0WmQLAC6lyxhjWgOfr16HpYHS1r5DZcAJqmH8mr6WyqtwhtsrJQWalZCYIXupQ8zaTiopRGprWAbfLJTeT13KmwXIcp_vzXkS_kzZKZX8m6wd9e76AN2dbfOoD_AL4gdCw
link.rule.ids 780
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acetazolamide+therapy+for+hypochloremic+metabolic+alkalosis+in+pediatric+patients+with+heart+disease&rft.jtitle=American+journal+of+therapeutics&rft.au=Moffett%2C+Brady+S&rft.au=Moffett%2C+Tiffany+I&rft.au=Dickerson%2C+Heather+A&rft.date=2007-07-01&rft.issn=1075-2765&rft.volume=14&rft.issue=4&rft.spage=331&rft_id=info:doi/10.1097%2FMJT.0b013e3180a72154&rft_id=info%3Apmid%2F17667206&rft_id=info%3Apmid%2F17667206&rft.externalDocID=17667206
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1075-2765&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1075-2765&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1075-2765&client=summon